Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models

14 Jun 2022

Abstract excerpt

INTRODUCTION: The effect of random error on the performance of blood-based biomarkers for Alzheimer's disease (AD) must be determined before clinical implementation. METHODS: We measured test-retest variability of plasma amyloid beta (Aβ)42/Aβ40, neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated tau (p-tau)217 and simulated effects of this variability on biomarker performance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Dementia and Cognitive Impairment Research
Share to Intracerebral and Subarachnoid Hemorrhage Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35699240
DOI: 10.1002/alz.12706

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction modelsPMID 35699240Read ↗

Biological variation estimates of Alzheimer’s disease plasma biomarkers in healthy individualsSemantic proximity Read ↗

The plasma p‐tau217/BD‐tau ratio improves biomarker short‐term variability in memory clinic patientsSemantic proximity Read ↗

Plasma biomarkers predict amyloid conversion and cognitive decline in cognitively unimpaired adultsSemantic proximity Read ↗

Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsSemantic proximity Read ↗

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer’s diseaseSemantic proximity Read ↗

The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin studySemantic proximity Read ↗

Population-based reference equations and Z-scores for blood biomarkers of neurodegenerative diseasesSemantic proximity Read ↗

Clinicopathological and prognostic correlations of plasma biomarkers in neurodegenerative diseasesSemantic proximity Read ↗

Biomarker Variability Limits Individualized Amyloid Time Estimation in Alzheimer DiseaseSemantic proximity Read ↗

Development and clinical validation of blood-based multibiomarker models for the evaluation of brain amyloid pathologySemantic proximity Read ↗

Disentangling relationships between Alzheimer's disease plasma biomarkers and established biomarkers in patients of tertiary memory clinicsSemantic proximity Read ↗

Consensus Risk Modeling and Uncertainty Quantification of Alzheimer’s Disease Using 5ADCSI Plasma Biomarkers and Multiple External Machine-Learning FrameworksSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.